Greenwich Beneish M Score

GLSI
 Stock
  

USD 8.85  0.37  4.36%   

This module uses fundamental data of Greenwich Lifesciences to approximate the value of its Beneish M Score. Greenwich Lifesciences M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please check Greenwich Lifesciences Piotroski F Score and Greenwich Lifesciences Altman Z Score analysis.
  
Refresh
Greenwich Lifesciences Debt to Equity Ratio is most likely to increase slightly in the upcoming years. The last year's value of Debt to Equity Ratio was reported at 0.014. Greenwich Lifesciences Debt to Equity Ratio is most likely to increase slightly in the upcoming years. The last year's value of Debt to Equity Ratio was reported at 0.014
At this time, it appears that Greenwich Lifesciences is an unlikely manipulator. The earnings manipulation may begin if Greenwich Lifesciences' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Greenwich Lifesciences executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Greenwich Lifesciences' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-5.4
Beneish M Score - Unlikely Manipulator
Elasticity of ReceivablesN/AFocus
Asset QualityN/AFocus
Expense CoverageN/AFocus
Gross Margin StrengsN/AFocus
Accruals FactorN/AFocus
Depreciation ResistanceN/AFocus
Net Sales GrowthN/AFocus
Financial Leverage Condition1.37Focus

Greenwich Lifesciences Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Greenwich Lifesciences' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Selling General and Administrative Expense992.8 KM
Sufficiently Down
Increasing
Slightly volatile
Depreciation Amortization and AccretionK3.6 K
Significantly Up
Increasing
Slightly volatile
Total Assets22.4 M27.2 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities395.3 K385.2 K
Fairly Up
Decreasing
Slightly volatile
Current Assets22.4 M27.2 M
Significantly Down
Increasing
Slightly volatile
Assets Non Current18.5 K17.9 K
Sufficiently Up
Decreasing
Slightly volatile
Current Liabilities575 K385.2 K
Way Up
Increasing
Very volatile
Liabilities Non Current8.5 M8.6 M
Slightly Down
Decreasing
Slightly volatile
Total Debt317.1 K247.6 K
Significantly Up
Decreasing
Slightly volatile
Debt Current317.1 K247.6 K
Significantly Up
Decreasing
Slightly volatile

Greenwich Lifesciences Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Greenwich Lifesciences' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Greenwich Lifesciences in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Greenwich Lifesciences' degree of accounting gimmicks and manipulations.

About Greenwich Lifesciences Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

3,990.33

Share
Greenwich Lifesciences Depreciation Amortization and Accretion is most likely to increase significantly in the upcoming years. The last year's value of Depreciation Amortization and Accretion was reported at 3,612

About Greenwich Lifesciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Greenwich Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Greenwich Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Greenwich Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Greenwich Lifesciences Investors Sentiment

The influence of Greenwich Lifesciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Greenwich. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Greenwich Lifesciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Greenwich Lifesciences' short interest history, or implied volatility extrapolated from Greenwich Lifesciences options trading.

Current Sentiment - GLSI

Greenwich Lifesciences Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Greenwich Lifesciences. What is your judgment towards investing in Greenwich Lifesciences? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Greenwich Lifesciences Piotroski F Score and Greenwich Lifesciences Altman Z Score analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
110.2 M
Return On Assets
-0.15
Return On Equity
-0.24
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.